[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603924":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":53,"collaborators":25,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":25,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":25,"studyType":68,"phases":69,"briefSummary":72,"conditions":73,"keywords":25,"overallStatus":75,"whyStopped":25,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: Dose Escalation","EXPERIMENTAL","Dose-escalation study of ZG005 in combination with Gecacitinib and Chemotherapy.",[13,14],"Drug: ZG005","Drug: Gecacitinib",{"label":16,"type":10,"description":17,"interventionNames":18},"Part 2: Dose Expansion","Cohort A: HER2-negative gastric or gastroesophageal junction adenocarcinoma; Cohort B: Esophageal squamous cell carcinoma; Cohort C: other Solid Tumors.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","ZG005","ZG005 20mg\u002Fkg; once every 3 weeks；IV infusion",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Gecacitinib","Gecacitinib for dose escalations are set as 100mg Bid po. Gecacitinib for dose expansion will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.",[9,16],[31],{"name":32,"affiliation":5,"role":33},"Jason Wu","STUDY_CHAIR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Bo Liu","CONTACT","051257309965","liub@zelgen.com",[41],{"facility":42,"status":25,"city":43,"state":44,"zip":25,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":25},"Chinese PLA General Hosptial","Beijing","Beijing Municipality","China","CN",{"type":48,"coordinates":49},"Point",[50,51],116.39723,39.9075,{"lat":51,"lon":50},{"type":54,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100603924","phase-1-study-of-zg005-in-combination-with-gecacitinib-and-chemotherapy-for-participants-with-advanced-solid-tumors-100603924",false,"NCT07142837","Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors","A Study to Evaluate the Efficacy and Safety of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n* Fully understand the study and voluntarily sign the informed consent form.\n* Male or female 18-75 years of age.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.\n* PART 1: Histologically confirmed unresectable locally advanced, recurrent, or metastatic solid tumors.PART 2 Cohort A: Histologically confirmed unresectable locally advanced, recurrent, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. Cohort B: Histologically confirmed unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma. Cohort C: Histologically confirmed unresectable locally advanced, recurrent, or metastatic other solid tumors.\n* Life expectancy ≥ 3 months.\n\nExclusion Criteria:\n\n* participants were deemed unsuitable for participating in the study by the investigator for any reasons.","ALL","18 Years","75 Years",{"count":66,"type":67},153,"ESTIMATED","INTERVENTIONAL",[70,71],"PHASE1","PHASE2","This is a multicenter, open-label phase I\u002FII study for participants with advanced solid tumors who have failed prior immune checkpoint inhibitor therapies.",[74],"Advanced Solid Tumor","NOT_YET_RECRUITING","2025-08-25",{"date":78,"type":79},"2025-08-27","ACTUAL",{"date":81,"type":67},"2025-09",{"date":83,"type":67},"2027-12",{"name":5,"class":6},1]